GE HealthCare expands invasive cardiology solutions portfolio with AltiX AI.i for elevated experience in catheterization lab and electrophysiology procedures

• AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab can enhance efficiency and precision care for multiple types of cardiac procedures

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the launch of the AltiX AI.i edition of Mac-Lab™, CardioLab™ and ComboLab™. The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features that can streamline workflow and enhance interoperability, while upholding strong cybersecurity standards.

Cardiovascular disease (CVD) has nearly doubled over the past three decades, affecting more than 500 million people worldwide. During this period, both deaths and disabilities due to CVD have been on the rise globally.¹ As cardiac cases continue to rise, there is an urgent need for tools that improve the efficiency of cardiac cath and EP procedures. Efficient diagnosis and therapy are key elements of addressing the growing demand for care.

“AltiX AI.i is built on more than two decades of experience, leadership and innovation in invasive cardiology to enhance cath labs and EP procedures and empower clinicians to deliver the best possible outcomes,” said Jyoti Gera, CEO, CardioVascular & Interventional Solutions, GE HealthCare. “By automating routine tasks and streamlining workflow, AltiX AI.i allows clinicians to focus on what truly matters – providing exceptional patient care.”

Mac-Lab for cardiac catheterization

The AltiX AI.i edition of Mac-Lab recording system combines functionality with workflow optimization. Clinicians can adopt this solution to elevate the cath lab user experience. The integration of the diastolic pressure ratio (dPR) algorithm allows users to easily perform this measurement, and builds on its ability to capture diastolic hyperemia-free ratio (DFR) measurements. These measurements are used to assess the severity of coronary artery disease. Mac-Lab provides optional Cath Lab Command Center access with a large display, advanced video and layouts, and customized documentation tools for a better user experience.

CardioLab for EP procedures

For EP procedures, the AltiX AI.i edition of CardioLab offers improved signal quality for visualization of physiological signals using the Prucka™ 3 digital amplifier. Prucka 3 is a solution that reduces environmental noise, maintains high signal fidelity and provides new signal-filtering capabilities for more advanced evaluations.² The latest CardioLab edition showcases GE HealthCare’s collaboration with Volta Medical, Volta Interface, which utilizes PruckaStream to share real-time data to inform its Volta AF-Xplorer™ decision support system. The feature is designed to support clinicians with real-time assessments using artificial intelligence (AI) to automatically assess areas believed to initiate or maintain atrial fibrillation drivers. For an optimal visual experience, users can also harness the EP Command Center.

ComboLab for a comprehensive solution

ComboLab seamlessly integrates EP and hemodynamic recording into a single system, offering versatile functionality for both cath lab procedures and EP exams. ComboLab merges the best of Mac-Lab and CardioLab to give clinicians a comprehensive solution to manage various cardiac procedures in one location. Its familiar interface and workflow ease the learning curve, and its capability to document and export diagnostic data helps capture more information at the point of care.

"The introduction of AltiX AI.i reinforces our commitment to advancing cardiac care. These improved solutions are designed to enhance diagnostic and therapeutic capabilities, which are crucial for diagnosing and treating various heart conditions," said Arnaud Marie, General Manager, Interventional Solutions, GE HealthCare. "This launch is an important step in our ongoing mission to equip healthcare providers with interventional solutions that evolve alongside their needs."

In recognition of its innovation and leadership, GE HealthCare was recently honored by Frost & Sullivan as the 2024 Company of the Year in the Global Next-Generation EP Labs Industry. This prestigious award highlights GE HealthCare's commitment to growth and excellence in the field.

GE HealthCare will showcase the AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab at the European Heart Rhythm Association (EHRA) 2025 annual congress taking place on March 30 - April 1 in Vienna, Austria and Heart Rhythm Society (HRS) 2025 annual meeting on April 24 - April 27 in San Diego. AltiX AI.i is available for order in the United States and will launch in global markets later this year. * Consult with your GE HealthCare sales representative for more information on the availability of AltiX AI.i in your country. For more information, visit: https://www.gehealthcare.com/products/invasive-cardiology.

* AltiX AI.i is 510(k) cleared and CE mark pending.

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

¹ Roth, G, Mensah, G, Johnson, C. et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. JACC. 2020 Dec, 76 (25) 2982–3021.
https://doi.org/10.1016/j.jacc.2020.11.010
² GE HealthCare Data on File